# Zenas BioPharma, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Zenas BioPharma, Inc.). ## Overview Zenas BioPharma is a U.S.-based clinical-stage biopharmaceutical company focused on immunology and inflammation therapies for autoimmune diseases. Its pipeline includes obexelimab, orelabrutinib, ZB021, ZB022, ZB002, ZB004, and partnered regional programs such as ZB001 in greater China. ## Products & services • Obexelimab immunology therapy • Orelabrutinib development program • ZB021 oral IL-17AA/AF inhibitor • ZB022 oral brain-penetrant TYK2-JH2 inhibitor • ZB002 anti-TNFα monoclonal antibody • ZB004 CTLA-4-Ig fusion protein • ZB001 / VRDN-001 regional program in greater China - **Lead immunology programs** (55%) — Core clinical and partnered assets centered on obexelimab and orelabrutinib for autoimmune and I&I diseases. - **Early-stage pipeline** (20%) — Discovery and IND-enabling assets including ZB021 and ZB022 aimed at future clinical entry. - **Other internal programs** (15%) — Additional proprietary I&I candidates such as ZB002 and ZB004 that may be advanced with partners. - **Regional partnered programs** (10%) — Licensed or sublicensed programs such as ZB001/VRDN-001 in greater China. - Obexelimab immunology therapy - Orelabrutinib development program - ZB021 oral IL-17AA/AF inhibitor - ZB022 oral brain-penetrant TYK2-JH2 inhibitor - ZB002 anti-TNFα monoclonal antibody - ZB004 CTLA-4-Ig fusion protein - ZB001 / VRDN-001 regional program in greater China ## Customers Zenas primarily serves pharmaceutical partners, licensees, and collaboration counterparties rather than end patients directly. Its commercial model is built around out-licensing, regional sublicensing, and future commercialization of approved therapies in the U.S. and Europe. If products are approved, hospitals, specialists, and healthcare systems would become the end-market buyers through prescription and reimbursement channels. - **Biopharma licensees and partners** (primary) — Companies such as BMS, Zai, Tenacia, and other collaborators that buy regional rights, development access, or royalty streams. - **Future specialty prescribers** (secondary) — Rheumatologists, immunologists, and other specialists who would prescribe approved I&I therapies. - **Payers and health systems** (secondary) — Insurers and healthcare systems that influence uptake through reimbursement and formulary access. - **Clinical trial ecosystem** (primary) — CROs, CMOs, and research sites that support development, manufacturing, and trial execution. - Pharma partners that license regional development and commercialization rights - Collaboration partners funding or sharing clinical development work - Future U.S. and European healthcare providers if products are approved - Specialists treating autoimmune and inflammatory diseases - Payers and health systems that determine access after approval ## Geography Zenas is headquartered in the United States and expects to build commercialization capabilities in the U.S. and Europe if products are approved. Its current development and partnering footprint also extends into Asia, including Japan, South Korea, Taiwan, Hong Kong, Singapore, Australia, and greater China through regional agreements. - Headquartered in the United States - Plans U.S. and Europe commercialization infrastructure - BMS territory covers Japan, South Korea, Taiwan, Hong Kong, Singapore, Australia - Greater China is a key partnered region for ZB001 - Clinical and supply chain activity depends on third-party global partners ## Strategy Zenas is building an immunology-focused pipeline through product candidate acquisition, internal development, and selective partnering. The company’s model combines global rights on some assets with regional out-licensing on others, while preparing for eventual self-commercialization in core Western markets. - **Advance obexelimab toward late-stage and approval milestones** (short-term) — It is the most advanced asset and the anchor for future commercialization and royalty economics. - **Expand the pipeline with ZB021 and ZB022** (medium-term) — New assets broaden the immunology platform and create future clinical optionality. - **Use regional partnerships to monetize non-core geographies** (medium-term) — Out-licensing can reduce capital needs while preserving upside through royalties and milestones. - **Prepare commercial infrastructure in the U.S. and Europe** (medium-term) — Direct commercialization would allow Zenas to capture more value if lead assets are approved. - Advance obexelimab and other I&I assets through clinical development - Use partnering to fund development and expand geographic reach - Build U.S. and Europe commercialization capabilities over time - Maintain optionality between self-commercialization and licensing - Diversify the pipeline with early-stage and partnered programs ## Risks Zenas faces the typical risks of a clinical-stage biopharma company: clinical failure, regulatory setbacks, and the need for substantial external funding before product sales begin. Its reliance on third-party CMOs, collaboration partners, and regional licensees also creates execution and supply-chain risk across multiple geographies. - **Clinical development failure** [critical] — Pipeline assets may not show sufficient efficacy or safety to advance or win approval. - **Capital raising and dilution** [high] — The company expects to fund operations externally until meaningful product revenue exists. - **Manufacturing and supply disruption** [high] — Clinical and future commercial supply depends on third-party CMOs and partners. - **Partner concentration and regional execution** [high] — Out-licensed territories and sublicenses reduce direct control over development and commercialization. - **Cybersecurity and geopolitical disruption** [medium] — Clinical data, remote work, and third-party systems can be disrupted by attacks or conflicts. - No approved products, so value depends on clinical and regulatory success - Future funding needs may force dilution or unfavorable partnering terms - Single-source or limited-source manufacturing can disrupt trials and launches - Partner dependence can limit control over timing, economics, and execution - Cybersecurity and geopolitical disruptions can affect trials and operations ## Accounting The most important accounting issue is revenue recognition from licenses, collaborations, milestones, and royalties, which can be lumpy and depend on contract terms and achievement of events. Investors should also watch accrued R&D expenses, fair value estimates for financing instruments, and any impairment or valuation judgments tied to development-stage assets and contingent rights. - **License and collaboration revenue recognition** — Can create volatile revenue unrelated to current operating scale - **Accrued research and development expenses** — Affects quarterly R&D expense and operating loss - **Fair value measurement of financing instruments** — Can affect reported equity and non-cash gains or losses - **Impairment and valuation of in-licensed programs** — Potential write-downs if programs underperform - License and collaboration revenue depends on milestone timing and contract terms - Royalty and sales-based income will be recognized only when underlying sales occur - Accrued R&D estimates affect reported operating expenses and period comparability - Fair value judgments matter for financing instruments and contingent consideration - Development-stage assets may require impairment or valuation reassessment --- *Last updated: 2026-04-29T05:11:37.584162+00:00*